The Burden of Rheumatoid Arthritis in Spain

Andrade, Paula; Sacristán, José Antonio; Rentero, Maria Luz; Hammen, Volker; Dilla, Tatiana

doi:10.4172/2471-268x.1000126

Cited by 3 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, the association of episodes with gastrointestinal diseases was also frequent, which has been shown to be consistent with other data in the literature and seems to have been increased in relation to the evolution of RA treatment [20,23].…”

Section: Discussionsupporting

confidence: 92%

“…In our study, the rate of hospitalization for RA in women seems to be much higher than that for men what seems to be in the same direction as observed by other studies [18] [20]; furthermore, the rate of hospitalization increased with age, reflecting a trend that is consistent with the literature [10,11].…”

Section: Discussionsupporting

confidence: 92%

“…The hospital stay has been significantly reduced during the period studied from 8 to 6 days, despite which, the total cost of rheumatoid arthritis has increased. This is due to the increase in hospitalizations for this disease and the new biological medications, which have significantly increased the treatment of this disease [20].…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Hospitalization burden and comorbidities of patients with rheumatoid arthritis in Spain during the period 2002–2017

Gil-Conesa

Del-Moral-Luque

Gil-Prieto

et al. 2020

BMC Health Serv Res

View full text Add to dashboard Cite

Background: Rheumatoid arthritis (RA) is a chronic autoimmune rheumatic disease that is associated with multiple comorbidities and has a significant economic impact on the Spanish health system. The objective of this study was to estimate the rates of hospitalization of rheumatoid arthritis in Spain, and describing hospitalization rates and their changing by age, region, RA variant, and when RA as a main cause of hospitalization or a comorbidity. Methods: Observational descriptive study that reviewed hospital records from the CMBD. We included all hospitalizations of patients in Spain whose main diagnosis or comorbidity in the ICD-9-CM was rheumatoid arthritis during the period of 2002-2017. Results: A total of 315,190 hospitalizations with the RA code were recorded; 67.3% were in women. The mean age of the patients was 68.5 ± 13.9 years. The median length of hospital stay was 7 days (IQR 3-11 days). In 29,809 of the admissions, RA was coded as the main diagnosis (9.4%). When RA was not coded as the main diagnosis, the most frequent main diagnoses were diseases of the circulatory system (18.9%) and diseases of the respiratory system (17.4%). The hospitalization rate during the period of 2002-2017 was 43.8 (95% CI: 43.7-44.0) per 100,000 inhabitants and constantly increased during the period. The total cost for the healthcare system was 1.476 million euros, with a median of 3542 euros per hospitalization (IQR 2646-5222 euros). Conclusions: In Spain, the hospitalization rate of patients with RA increased during the study period, despite the decrease in the hospitalization rate when RA was the main diagnosis.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionsupporting

confidence: 92%

See 1 more Smart Citation

Hospitalization burden and comorbidities of patients with rheumatoid arthritis in Spain during the period 2002–2017

Gil-Conesa

Del-Moral-Luque

Gil-Prieto

et al. 2020

BMC Health Serv Res

View full text Add to dashboard Cite

show abstract

“…In our study, the rate of hospitalization for RA in women seems to be much higher than that for men what seems to be in the same direction as observed by other studies (18) (20) ; furthermore, the rate of hospitalization increased with age, reflecting a trend that is consistent with the literature (10,11).…”

Section: Discussionsupporting

confidence: 92%

Hospitalization burden and comorbidities of patients with rheumatoid arthritis in Spain during the period 2002-2017

Gil-Conesa

Del-Moral-Luque

Gil-Prieto

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Rheumatoid arthritis (RA) is a chronic autoimmune rheumatic disease that is associated with multiple comorbidities and has a significant economic impact on the Spanish health system. The objective of this study was to estimate the rates of hospitalization of rheumatoid arthritis in Spain, and describing hospitalization rates and it's changing by age, region, RA variant, and when RA as a main cause of hospitalization or a comorbidity. Methods: Observational descriptive study that reviewed hospital records from the CMBD. We included all hospitalizations of patients in Spain whose main diagnosis or comorbidity in the ICD-9-CM was rheumatoid arthritis during the period of 2002-2017. Results: A total of 315,190 hospitalizations with the RA code were recorded; 67.3% were in women. The mean age of the patients was 68.5 ± 13.9 years. The median length of hospital stay was 7 days (IQR 3-11 days). In 29,809 of the admissions, RA was coded as the main diagnosis (9.4%). When RA was not coded as the main diagnosis, the most frequent main diagnoses were diseases of the circulatory system (18.9%) and diseases of the respiratory system (17.4%). The hospitalization rate during the period of 2002-2017 was 43.8 (95% CI: 43.7-44.0) per 100,000 inhabitants. The total cost for the healthcare system was 1.476 million euros, with a median of 3,542 euros per hospitalization (IQR 2,646-5,222 euros). Conclusions: In Spain, the hospitalization rate of patients with RA increased during the study period, despite the decrease in the hospitalization rate when RA was the main diagnosis.

show abstract

“…Rheumatoid arthritis (RA) is one of the most common autoimmune diseases, with a prevalence of 0.5% in Spain,1 which is similar to the worldwide prevalence of 0.5–1.0% 2. This chronic, progressive and disabling systemic autoimmune disease is caused by an interaction of genetic and environmental factors resulting in an increased activity of the pro-inflammatory pathways and auto-antibodies targeting the synovium, cartilage, and bone, leading to joint damage and loss of function.…”

Section: Introductionmentioning

confidence: 90%

<p>Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain</p>

Schlueter

Finn

Díaz

et al. 2019

CEOR

Self Cite

View full text Add to dashboard Cite

Background: Baricitinib is an oral janus kinase inhibitor for the treatment of rheumatoid arthritis (RA) and is approved in Europe for use in adults with moderately-to-severely active RA and an inadequate response or intolerance to conventional synthetic disease-modifying antirheumatic drug (csDMARD) therapy. To date, no economic evaluations have assessed the cost-effectiveness of baricitinib in the Spanish setting. Objectives: To evaluate the cost-effectiveness of baricitinib versus adalimumab for the treatment of moderately-to-severely active RA in the Spanish setting. Methods: A discrete event simulation model was developed in Microsoft Excel. Costs and outcomes were estimated over a lifetime horizon using the Spanish national payer perspective. The model compared baricitinib 4 mg once daily in combination with methotrexate with adalimumab 40 mg every other week in combination with methotrexate. Effectiveness and physical function were captured using the American College of Rheumatology criteria and the Health Assessment Questionnaire–Disability Index, input values of which were derived from a phase 3, double-blind, placebo- and active-controlled trial (RA-BEAM; funded by Eli Lilly and Incyte; ClinicalTrials.gov number, NCT01710358). Costs are presented in Euros, 2018 values. Results: In the base case analysis, baricitinib was associated with a quality-adjusted life year gain of 0.09 years over a lifetime horizon, at an incremental cost of –€558 versus adalimumab. Results of various scenario analyses and probabilistic sensitivity analysis generally were consistent with the base case analysis. Conclusion: This analysis suggests that baricitinib is a cost-effective treatment option compared to adalimumab for Spanish patients with moderately-to-severely active RA and a previous inadequate response or intolerance to csDMARD therapy.

show abstract

The Burden of Rheumatoid Arthritis in Spain

Cited by 3 publications

References 0 publications

Hospitalization burden and comorbidities of patients with rheumatoid arthritis in Spain during the period 2002–2017

Hospitalization burden and comorbidities of patients with rheumatoid arthritis in Spain during the period 2002–2017

Hospitalization burden and comorbidities of patients with rheumatoid arthritis in Spain during the period 2002-2017

<p>Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain</p>

Contact Info

Product

Resources

About